Cresco Labs Takes Pennsylvania Retail Lead With $50 Million PharmaCann Deal

Cresco Labs is now Pennsylvania’s largest medical marijuana retailer after closing a $50 million purchase of nine dispensaries from PharmaCann.

The Chicago-based multi-state operator said it acquired 100 percent of PharmaCann Penn, LLC, adding nine operating medical marijuana stores across the commonwealth. The $50 million price was paid with cash and a seller note. Cresco said the deal closed on a cash-free, debt-free basis with an agreed level of working capital.

The company called Pennsylvania the second-largest medical marijuana market in the country, with more than $1.1 billion in sales last year. Cresco said the PharmaCann stores push it to No. 1 in statewide retail while it remains the state’s top wholesaler. Management argued that pairing more storefronts with its existing cultivation and brand network gives it a scale smaller operators cannot easily match.

CEO Charlie Bachtell said the company is putting capital into markets where it already has an edge. “We are focused on deploying capital into opportunities that strengthen our competitive position and generate attractive long-term returns,” he said. “This transaction expands our retail footprint in a core market through a highly strategic acquisition while creating additional opportunities to leverage our existing infrastructure.”

Bachtell described Pennsylvania as one of Cresco’s core states. “Scale and vertical integration create durable competitive advantages,” he said. Adding retail doors to the company’s wholesale business, he added, “reinforces our position as the consolidator of choice in the markets that matter most.”

Cresco said the acquisition should lift revenue, margins, and cash flow immediately. The company sells products under brands including Cresco, High Supply, FloraCal, Good News, Wonder Wellness Co., Mindy's, and Remedi and operates stores under the Sunnyside name.

The PharmaCann purchase is not Cresco’s first move in Pennsylvania. The MSO earlier bought Cure Pennsylvania and Laurel Harvest and has opened additional Sunnyside locations. Those deals expanded its growth, processing, and wholesale presence. This one is aimed at the storefronts that sell to patients.

Pennsylvania still runs a medical-only program with a limited number of licenses. That has made existing dispensaries valuable and favored well-financed multi-state operators that can buy rather than wait for new permits. Cresco presented nine ready-to-operate stores as a faster way to lock in retail leadership than building locations one at a time.

The $50 million price also shows that licensed, cash-generating stores in large medical markets still command real money even as federal cannabis policy remains unsettled. For patients, more of the state’s retail access now sits under a single operator that already supplies a large share of product into Pennsylvania dispensaries.

Cresco did not name the nine store addresses in its announcement. It said the locations are open and complementary to its existing Pennsylvania network.